Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy
In patients with nonobstructive HCM, mavacamten did not significantly improve peak oxygen uptake or decrease symptoms as compared with placebo, and more patients had a reduction in LVEF with mavacamten.
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 11, 2025
|
| In: |
The New England journal of medicine
Year: 2025, Volume: 393, Issue: 10, Pages: 961-972 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa2505927 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa2505927 Verlag, lizenzpflichtig, Volltext: https://www.nejm.org/doi/full/10.1056/NEJMoa2505927 |
| Author Notes: | M.Y. Desai, A.T. Owens, T. Abraham, I. Olivotto, P. Garcia-Pavia, R.D. Lopes, P. Elliott, F. Fernandes, N. Verheyen, L. Maier, B. Meder, O. Azevedo, H. Kitaoka, K. Wolski, Q. Wang, W. Jaber, L. Mitchell, J. Myers, T. Rano, Z. Gong, Y. Zhong, S. Carter-Bonanza, V. Florea, R. Aronson, and S.E. Nissen |
| Summary: | In patients with nonobstructive HCM, mavacamten did not significantly improve peak oxygen uptake or decrease symptoms as compared with placebo, and more patients had a reduction in LVEF with mavacamten. |
|---|---|
| Item Description: | Online veröffentlicht am: 30. August 2025 Gesehen am 27.05.2026 |
| Physical Description: | Online Resource |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa2505927 |